A RESEARCH ON THE ENHANCEMENT OF COCAINE HYDROLASE FOR THERAPEUTIC INTERVENTION IN COCAINE-RELATED AGGRESSION

Shi Yanhua[1], Farra Aidah Jumuddin[2]

ABSTRACT

A public health emergency exists due to the major problem of ineffective medicinal treatments for cocaine addiction. The purpose of this study was to develop a synthetic enzyme, cocaine hydrolase (CocH), that would mitigate the negative effects of cocaine on the brain and body. This enzyme would rapidly degrade cocaine into harmless metabolites. To improve CocH's selectivity, stability, and catalytic activity while reducing its off-target effects, the researcher explore the prospect of structural optimization in this work. Enzyme design, in vivo and in vitro characterization of CocH variants, and preclinical evaluation of therapeutic potential are the primary goals of research in this field. Animal models of drug-induced behavioral responsiveness and cocaine metabolism were both enhanced by enhanced CocH. The study also investigates potential immunogenicity, safety, and delivery techniques to ensure that CocH is suitable for clinical usage. There is mounting evidence that enzyme-based therapy may be an effective new way to treat cocaine addiction, and this research adds to that body of knowledge. Because of the devastating impacts on people's mental health, relationships, and ability to make ends meet, cocaine addiction is becoming an increasingly pressing issue in public health. Despite extensive research, pharmacological therapies for cocaine addiction have not proven successful. Because of its extraordinary rate of degradation relative to the body's natural metabolism, an engineered enzyme known as cocaine hydrolase (CocH) is the principal subject of this study. Benzoic acid and ecgonine methyl ester are two non-pharmacological metabolites of cocaine.

Keywords: *Pharmacological Metabolites, Metabolism, Drug Addiction, Cocaine.*

1. INTRODUCTION

Creating a safe and efficient gene-transfer delivery system that can produce vast amounts of hydrolase is the top priority. This will be useful for recovering addicts in their fight against relapse. This enzyme completely or significantly reduces cocaine's effects on the brain's reward areas. Butyrylcholinesterase (BChE) is an essential enzyme for the correct metabolism of cocaine. An Fc-fused hCocH dimer (hCocH-Fc) was considered and found during the creation of the long-acting hCocHs. The catalytic antibody serves as its inverse. With a much longer biological half-life and high catalytic activity against cocaine, hCocH-Fc is an excellent choice. A single dose of hCocH-Fc, given 20 days after injection, sped up cocaine metabolism and reduced cocaine-induced hyperactivity in rats. To treat cocaine addiction in humans, the hCocH-Fc may allow dose every two to four weeks, or even longer, due to the fact that the biological half-life of a protein medicine is much longer in humans compared to rats. The main goal of pharmacokinetic agents in the treatment of cocaine addiction is to keep blood cocaine levels below the lowest effective concentration (21). Enzymes with a broad half-life in living things and high catalytic effectiveness against cocaine would be the best option for treating cocaine addiction. Among the several metabolic enzymes involved in the breakdown of cocaine is BChE, which produces metabolites that do not have any physiological effect. Unfortunately, the wild-type BChE enzyme can't improve the naturally occurring (-)-cocaine since its catalytic efficiency (kcat/KM) is too low (kcat = 4.1 min−1 and KM = 4.5 μM). This approach to the development of prospective CocHs for the treatment of cocaine addiction was the major goal of the study reported here. The newly discovered cocH3 protein, like Fc(M3), the A1V/D142E/L144M mutant (33) of Fc, possesses an IL-2 signal peptide bound to its N-terminus. Following this, the tetramerization region (amino acid residues from #530 to #574) of CocH3 was deleted to further decrease the possibility of steric interference

between Fc(M3) and CocH3. After much discussion, the possibility of links (L) connecting the Fc(M3) and CocH3 domains was further examined. To optimize the PK profile, the researcher created and examined several Fc(M3)-L-CocH3 entities for their pharmacokinetic profiles in rats in relation to cocaine. Overall, the data showed that Fc(M3) fusion at the N-terminus of CocH3 was the most promising (Nitro et al., 2022).

2. BACKGROUND OF THE STUDY

Cocaine addiction impacts not only the individual struggling with the addiction, but also those closest to them and society at large. Because of its ability to block dopamine reuptake in the brain, cocaine produces euphoric effects and has a high potential for addiction. The risk of brain abnormalities, cardiovascular problems, and social dysfunction from long-term use makes an effective treatment an absolute need. Regardless of the conditions, the FDA has not yet approved any medicinal therapy for cocaine dependence (Pendolino et al., 2024). Although behavioral treatments are helpful, their effectiveness might vary, thus there is an urgent need for new, targeted approaches to treatment. One potential tool for combating cocaine addiction is cocaine hydrolase (CocH), a synthetic enzyme that imitates the action of butyrylcholinesterase (BChE) in humans. The slow metabolism of BChE prevents it from delaying the start of effects, even if it converts cocaine into inactive metabolites. Thanks to recent developments in protein engineering, more effective catalyst variants of CocH have been engineered. Cocaine is more easily broken down by this. To treat or prevent cocaine overdose, COCH is utilized since it either completely removes or greatly diminishes the drug's euphoric effects. This research aims to fill in some significant gaps in understanding of CocH by studying its biochemical properties, developing ways to enhance its activity via protein engineering, and evaluating its efficacy as a treatment in animal models. The

main objectives of this research are to gain understanding of enzyme-based cocaine therapies and to develop a novel, efficient medication to combat this pervasive issue. Methods of administration, safety, and efficacy studies of CocH will be discussed (Culerrier et al., 2024).

3. PURPOSE OF THE STUDY

Understanding the optimal usage of cocaine hydrolase (CocH) as a new therapeutic agent to treat cocaine addiction and abuse is the primary goal of this study. To lessen the drug's negative and positive effects, a new enzyme called cocaine hydrolase rapidly breaks it down into inert substances. Through the use of advanced protein engineering techniques, this effort aims to produce an enzyme that may dramatically increase the rate of cocaine clearance from the bloodstream by enhancing the catalytic efficiency of CocH. Another main goal is to determine whether or not CocH has therapeutic potential in reducing the behavioral and physiological effects of cocaine. To see whether it can reduce the rewarding effects of cocaine, the researcher will conduct tests on preclinical animals. whether it can, it may be a fantastic alternative to cocaine treatment. By investigating its immunogenicity, stability, and off-target effects, the researcher can guarantee that CocH is safe for clinical use. To ensure that the therapeutic effects of CocH are both immediate and long-lasting, the study investigates alternative administration modalities, such as gene therapy and direct protein injection. The goal of this research is to find an enzyme-based treatment for cocaine addiction that works better than current pharmacological treatments, so that those affected by drug abuse and acute cocaine toxicity may live a little easier lives. In order to quickly reduce the societal and public health costs associated with cocaine addiction, the researcher are aiming to discover a treatment that is both effective and safe for patients.

4. LITERATURE REVIEW

Everyone in the community feels the effects of substance misuse, and cocaine addiction in particular. The use of behavioral therapies, including CBT and contingency management, to treat cocaine addiction has a long history. When these drugs don't work to relieve symptoms because they come back so often, other pharmacological therapies are needed. There is a severe dearth of choices for those battling cocaine addiction as no medications have been authorized for treatment of this condition by the FDA. Research spanning centuries has consistently shown this to be true. Potentially effective treatments include those based on enzymes, which mimic the body's natural metabolic routes for drug elimination. Human butyrylcholinesterase (BChE) has the interesting property of degrading cocaine into inactive forms, but it is therapeutically ineffective because of its innately low catalytic efficiency (Zarka et al., 2020). A more effective variant of BChE, made possible by recent advances in protein engineering, is known as cocaine hydrolase (CocH), and it is far more efficient against cocaine. Scientific studies have shown that COCH may rapidly degrade cocaine, resulting in a lower blood concentration of the drug and a reduction in its hallucinogenic effects. Evidence from preclinical studies of CocH in animals models of cocaine overdose and cocaine-induced behaviors is encouraging. Furthermore, these results suggest that COCH may lessen the intoxicating effects of cocaine, which might result in less cravings and the absence of relapse motivation. To achieve long-term therapeutic advantages, it is essential to reduce the enzyme's immunogenicity, stabilize it in vivo, and improve its transport. An intriguing gene therapy strategy that could provide patients a new long-term treatment option is coenzyme H (CocH) expression using adeno-associated virus (AAV)-mediated delivery. It is also stressed in the literature that safety problems must be addressed (Wigerblad & Kaplan, 2023).

5. RESEARCH QUESTION

- What is the impact of Immunogenicity on Therapeutical Treatment of Cocaine Abuse Treatment?

6. RESEARCH METHODOLOGY

Quantitative research refers to studies that examine numerical readings of variables using one or more statistical models. The social environment may be better understood via quantitative research. Quantitative approaches are often used by academics to study problems that impact particular individuals. Objective data presented in a graphical format is a byproduct of quantitative research. Numbers are crucial to quantitative research and must be collected and analyzed in a systematic way. Averages, predictions, correlations, and extrapolating findings to larger groups are all possible with their help.

- **Research design:** Quantitative data analysis was conducted using SPSS version 25. The combination of the odds ratio and the 95% confidence interval provided information about the nature and trajectory of this statistical association. The p-value was set at less than 0.05 as the statistical significance level. The data was analyzed descriptively to provide a comprehensive understanding of its core characteristics. Quantitative approaches are characterized by their dependence on computing tools for data processing and their use of mathematical, arithmetic, or statistical analyses to objectively assess replies to surveys, polls, or questionnaires.
- **Sampling:** After pilot research with 20 Chinese Researcher, 1100 Rao-soft pupils were included in the final Investors. Male and female Researcher were picked at random and

then given a total of 1,455 surveys to fill out. A total of 1253 questionnaires were used for the calculation after 1300 were received and 47 were rejected due to incompleteness.

- **Data and Measurement:** A questionnaire survey served as the main data collector for the study. There were two sections to the survey: (A) General demographic information and (B) Online & non-online channel factor replies on a 5-point Likert scale. Secondary data was gathered from a variety of sources, with an emphasis on online databases.
- **Statistical Tools:** Descriptive Analysis was used to grasp the fundamental character of the data. The researcher applied ANOVA for the analysis of the data.

7. CONCEPTUAL FRAMEWORK



8. RESULT

❖ Factor analysis

One typical use of Factor Analysis (FA) is to verify the existence of latent components in observable data. When there are not easily observable visual or diagnostic markers, it is common practice to utilize regression coefficients to produce ratings. In FA, models are essential for success. Finding mistakes, intrusions, and obvious connections are the aims of modelling. One way to assess datasets produced by multiple regression studies is with the use of the Kaiser-Meyer-Olkin (KMO) Test. They verify that the model and sample variables are representative. According to the numbers, there is data duplication. When the proportions are less, the data is easier to understand. For KMO, the output is a number between zero and one. If the KMO value is between 0.8 and 1, then the sample size should be enough. These are the permissible boundaries, according to Kaiser: The following are the acceptance criteria set by Kaiser:

A dismal 0.050 to 0.059, subpar 0.60 to 0.69

Middle grades often range from 0.70 to 0.79.

Exhibiting a quality point score between 0.80 and 0.89.

They are astonished by the range of 0.90 to 1.00.

Table 1: KMO and Bartlett's Test for Sampling Adequacy Kaiser-Meyer-Olkin measurement: .911

The outcomes of Bartlett's test of sphericity are as follows: Approximately chi-square degrees of freedom = 190 significance = 0.000

This confirms the legitimacy of claims made just for sampling purposes. Researchers used Bartlett's Test of Sphericity to ascertain the significance of the correlation matrices. A Kaiser-

Meyer-Olkin value of 0.911 indicates that the sample is sufficient. The p-value is 0.00 according to Bartlett's sphericity test. A positive outcome from Bartlett's sphericity test indicates that the correlation matrix is not an identity matrix.

Table: KMO and Bartlett's

KMO and Bartlett's Test		
Kaiser-Meyer-Olkin Measure of Sampling Adequacy.		.911
Bartlett's Test of Sphericity	Approx. Chi-Square	3252.968
	df	190
	Sig.	.000

The overall significance of the correlation matrices was further confirmed by using Bartlett's Test of Sphericity. A value of 0.911 was the Kaiser-Meyer-Olkin sampling adequacy. By using Bartlett's sphericity test, researchers found a p-value of 0.00. A significant test result from Bartlett's sphericity test demonstrated that the correlation matrix was not a correlation matrix.

❖ INDEPENDENT VARIABLE

➢ The Development of Cocaine Hydrolase

Cocaine hydrolase (CocH), an engineered enzyme, has the potential to rapidly break down cocaine into harmless metabolites such as benzoic acid and ecgonine methyl ester. Being derived from or based on human butyrylcholinesterase (BChE), changes significantly enhance the selectivity and catalytic effectiveness of CocH. To mitigate cocaine's damaging and intoxicating effects, CocH boosts the metabolic rate in the blood. For this reason, it may be useful as a medication to treat cocaine addiction, overdose, and related symptoms. Methods for treating both short-term and long-

term cocaine addictions may be supported by the fact that COCH blocks the brain connections that cocaine uses to produce its euphoric and reinforcing effects (Bentzley et al., 2021).

❖ FACTOR

➢ Immunogenicity

The capacity of a material, whether it a biological molecule, vaccine, or medication, to induce an immune response is known as its immunogenicity. Depending on the circumstances, this immunological response could have positive or negative effects. The goal of vaccine design is to elicit an immune response that can ward against a particular illness; this process is known as immunogenicity. The development of anti-drug antibodies (ADAs) may diminish the treatment's efficacy or produce severe responses, making immunogenicity a common and undesired side effect of biologic pharmaceuticals and therapeutic proteins. Immunogenicity is affected by a number of things. Substances are more likely to trigger an immune response if their molecular structures are different from the body's native proteins. Subcutaneous delivery increases the likelihood of an immunological response compared to intravenous treatment; hence the mode of administration is crucial. Immunogenicity may also be influenced by dosing frequency and frequency, as well as by genetics and immune system condition, which are personal traits of the patient (Winhusen et al., 2019).

❖ DEPENDENT VARIABLE

➢ Therapeutical Treatment of Cocaine Abuse Treatment

Therapeutic therapies use a wide range of medical and psychological treatments to alleviate, manage, or cure a specific mental or physical health condition. These tailored treatments aim to alleviate symptoms while simultaneously improving health and restoring normal functioning. Pharmacological treatments include medication, physical therapy include exercises and rehabilitation, psychological therapies include counseling and cognitive-behavioral therapy, and complementary therapies include acupuncture and massage. Therapeutic treatment seeks to do more than just alleviate symptoms; it also aspires to improve the patient's long-term health, prevent the illness from returning, and enhance their quality of life. Gathering detailed information on each patient's medical history, symptoms, and sickness severity is standard procedure for creating personalized treatment programs. Rehabilitation after accidents or operations, treatment of acute diseases, and management of long-term health conditions might all benefit from it (Osorio et al., 2024).

❖ Relationship between Immunogenicity and Therapeutical Treatment of Cocaine Abuse Treatment

When it comes to biologics, vaccines, and protein-based medications, there is a strong correlation between immunogenicity and therapeutic therapy. It is crucial to thoroughly assess immunogenicity throughout medication development and clinical usage since it may greatly affect the safety and effectiveness of therapeutic therapies. Certain therapeutic treatments, particularly biologics like gene therapies, enzyme replacements, and monoclonal antibodies, have the potential to unintentionally cause patients to mount an immune response. An immunogenic reaction may

cause the body to make antibodies that either neutralize the medication or change its pharmacokinetics; these antibodies are called anti-drug antibodies (ADAs). Therefore, it may be necessary to increase dosages or try an alternate therapy if the medication loses its effectiveness. The treatment's usefulness may be restricted in some instances due to unpleasant effects caused by immunogenicity, such as inflammation or hypersensitivity. Vaccines are one example of a therapeutic setting where immunogenicity is an intended result. The goal of developing vaccines is to protect humans from harmful microorganisms by stimulating an immune response. Vaccine efficacy is measured by how well it elicits an immunogenic response while minimizing serious side effects. Engineered less immunogenic molecules, altered delivery methods, and immunosuppressive co-treatments are some of the tactics used by researchers and doctors to control immunogenicity. Vaccines aim to elicit a specific immune response by using adjuvants and delivery mechanisms that are fine-tuned. To maximize the benefits and minimize the hazards of therapeutic treatments, it is vital to understand and regulate immunogenicity (Romo et al., 2023).

Based on the above discussion, the researcher formulated the following hypothesis, which was to analyze the relationship between Immunogenicity and Therapeutical Treatment of Cocaine Abuse Treatment .

H_{01}: "There is no significant relationship between Immunogenicity and Therapeutical Treatment of Cocaine Abuse Treatment"

H_1: "There is a significant relationship between Immunogenicity and Therapeutical Treatment of Cocaine Abuse Treatment"

Table 2: H_1 ANOVA Test

ANOVA					
Sum					
	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	39588.620	532	5655.517	693.487	.000
Within Groups	492.770	720	5.356		
Total	40081.390	1252			

This investigation yields remarkable results. The F value is 693.487, achieving significance with a p-value of .000, which is below the .05 alpha threshold. This means ***"H_1: There is a significant relationship between Immunogenicity and Therapeutical Treatment of Cocaine Abuse Treatment"*** The alternative hypothesis is accepted, whereas the null hypothesis is rejected.

9. CONCLUSION

The use of cocaine hydrolase (CocH) has led to notable progress in the treatment of cocaine use and addiction. Through optimization and genetic engineering, CocH has shown the ability to rapidly convert cocaine into inactive metabolites, reducing both the intoxicating effects and the toxicity risk associated with the drugs. It is feasible that the limitations of existing approaches may be addressed by merging this innovative enzyme-based treatment with behavioral treatments and more traditional pharmacological approaches. Efficacy in reducing cocaine-induced behaviors and preventing overdose has been shown in animal preclinical experiments, indicating that CocH may have therapeutic and preventive value. It has been shown that CocH may be altered to have therapeutic effects with extended half-lives via research into alternative delivery methods, such as gene therapy and recombinant protein injection. Improvements in enzyme stability, reduction of immunogenicity, and assurance of safety in clinical settings are only a few of the several outstanding challenges. Nevertheless, progress has been promising. The findings should be

carefully considered by those who are attempting to develop enzyme-based therapies for the prevention of drug overdoses and cocaine addiction. Additional human trials of COCH might shed light on a pressing public health problem by offering a fresh and effective method of treating cocaine. This research establishes the framework for a more comprehensive approach to addiction therapy by integrating cutting-edge biotechnology with established therapeutic procedures. Trimarchi et al say People battling a cocaine addiction may hope for improved outcomes in this way (Trimarchi et al., 2021).

REFERENCE

Trimarchi, M.; Bertazzoni, G.; Vinciguerra, A.; Pardini, C.; Simeoni, F.; Cittaro, D.; Bussi, M.; Lazarevic, D. Gene Expression Analysis in Patients with Cocaine-Induced Midline Destructive Lesions. Medicine 2021, 57, 861.

Romo N, Lorena A, Concejero T, Pavón L. Addressing gender - based violence in drug addiction Treatment : a systematic mapping review. Int J Ment Health Addict. 2023.

Osorio, M.; Velásquez, I.; Vargas, R.; Vanegas-García, A.; Rojas, M.; Vásquez, G.; Muñoz-Vahos, C. NETosis Secondary to the Use of Levamisole-Adulterated Cocaine: A Likely Underlying Mechanism of Vasculopathy. J. Toxicol. 2024, 2024, 7388799.

Winhusen TM, Theobald J, Lewis DF. Substance use outcomes in cocaine-dependent tobacco smokers: a mediation analysis exploring the role of sleep disturbance, craving, anxiety, and depression. J Subst Abuse Treat. 2019.

Bentzley BS, Han SS, Neuner S, Humphreys K, Kampman KM, Halpern CH. Comparison of treatments for cocaine use disorder among adults: a systematic review and meta-analysis. JAMA Netw Open. 2021.

Wigerblad, G.; Kaplan, M.J. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat. Rev. Immunol. 2023, 23, 274–288.

Zarka, F.; Veillette, C.; Makhzoum, J.P. A Review of Primary Vasculitis Mimickers Based on the Chapel Hill Consensus Classification. Int. J. Rheumatol. 2020, 2020, 8392542.

Culerrier, J.; Nguyen, Y.; Karadag, O.; Yasar Bilge, S.; Yildrim, T.D.; Ögüt, T.S.; Yazisiz, V.; Bes, C.; Celfe, A.; Yazici, A.; et al. Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: A multicentre retrospective case-control study. Rheumatology 2024, 63, 999–1006.

Pendolino, A.L.; Benshetrit, G.; Navaratnam, A.V.; To, C.; Bandino, F.; Scarpa, B.; Kwame, I.; Ludwig, D.R.; McAdoo, S.; Kuchai, R.; et al. The role of ANCA in the management of cocaine-induced midline destructive lesions or ENT pseudo-granulomatosis with polyangiitis: A London multicentre case series. Laryngoscope 2024, 134, 2609–2.

Nitro, L.; Pipolo, C.; Fadda, G.L.; Allevi, F.; Borgione, M.; Cavallo, G.; Felisati, G.; Saibene, A.M. Distribution of cocaine-induced midline destructive lesions: Systematic review and classification. Eur. Arch. Otorhinolaryngol. 2022, 279, 3257–3267.